A new weight loss pill has shown promise as a more convenient medication for adults with obesity and type 2 diabetes.

The once-daily pill appears to be effective and safe for these patients, according to a phase 3 trial funded by Eli Lilly, the makers of Mounjaro and Trulicity.

Adults with obesity and type 2 diabetes who took orforglipron—an oral small-molecule GLP-1 receptor agonist—in addition to lifestyle changes for around 72 weeks had a higher reduction in body weight than those who received a placebo.

While current injectable treatments for weight loss and blood sugar control in people with obesity and type 2 diabetes are effective, they require cold storage and come with the impracticality of and aversion to needles. Current pills for weight loss, meanwhile, require food and wate

See Full Page